v3.26.1
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2026
Mar. 31, 2025
Operating expenses:    
Research and development $ 6,845 $ 8,145
General and administrative 4,267 4,789
Intangible asset impairment charge 67,808 0
Fair value adjustment for contingent consideration (64,330) 1,924
Total operating expenses 14,590 14,858
Loss from operations (14,590) (14,858)
Fair value adjustment for debt 12,168 (444)
Fair value adjustment for warrants 31,116 0
Interest income 160 406
Other income (expense), net 1,719 (87)
Net income (loss) before income tax expense 30,573 (14,983)
Income tax benefit (expense) 5,339 (47)
Net income (loss) 35,912 (15,030)
Other comprehensive loss:    
Foreign currency translation adjustments (1,135) 2,045
Unrealized loss on available-for-sale securities (5) (53)
Total comprehensive income (loss) $ 34,772 $ (13,038)
Net income (loss) per share - basic (in USD per share) [1] $ 3.6 $ (3.42)
Weighted average shares of common stock outstanding - basic (in shares) [1] 9,120,267 4,394,119
Net income (loss) per share - diluted( (in USD per share) [1] $ 2.88 $ (3.42)
Weighted average shares of common stock outstanding - diluted (in shares) [1] 9,190,354 4,394,119
[1] Adjusted prior period net loss per share and weighted average of common shares outstanding to reflect the 1-for-10 reverse stock split effected on April 10, 2026.